mAP kinases (MAPKs) are signal transduction intermediates for endogenous and environmental stimuli in diverse systems, ncluding growth regulation, carcinogenesis, and development. Activator protein-1 (AP-1) transcription factors regulate expression of genes in response to endogenous and extracellular stimuli, including hormones, growth factors, phorbol ester tumor promoters, and other carcinogenic agents. MAPKs are upstream regulators of AP-1. The mechanisms of AP-1 regulation by MAPKs in vivo are thought to involve direct MAPK phosphorylation of AP-1 components or to be indirect via signalling intermediates between MAPK and AP-1. We have identified a family of seven MAPK related proteins (MAPKRPs), including ERK-2, which forms stable complexes in vivo with (AP-1 transcription factors. While AP-1 proteins may be MPKRP substrates, the stability of complexes is an important clue that protein-protein interactions between MAPKRPs and AP-1 may have novel regulatory significance.
The aim of this program is to investigate the regulatory significance.
The aim of this program is to investigate the identities and funcitons of these numerous stable mAPK-AP-1 complexes. The genes encoding several MAPKRPs will be cloned by screening a Lambda ZAP Express cDNA library. Protein kinase activity of MAPKRPs and mAPK-AP-1 complexes will be measured by in vitro kinase assays. The hypothesis that MAPKRP-AP-1 complexes bind to AP-1 DNA will be tested by electrophoretic mobility shift and AP-1 DNA affinity chromatography assays. This program is significant because it is likely to lead to cloning of novel MAPKRP genes encoding MAPKRPs that bind AP-1 in vivo and shed light on mechanisms of MAPK and AP-1 signal transduction. If mAPKRP-AP-1-DNA complexes are discovered, it may provide a new paradigm for signal transduction complexes at the site of DNA. Since MAPKs and AP-1 mediate responses to many carcinogenic effectors, this work has potential significance for elucidating mechanisms of neoplastic transformation.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
First Independent Research Support & Transition (FIRST) Awards (R29)
Project #
3R29CA073783-05S4
Application #
6803353
Study Section
Pathology B Study Section (PTHB)
Program Officer
Rosenfeld, Bobby
Project Start
1997-07-01
Project End
2004-06-30
Budget Start
2001-07-01
Budget End
2004-06-30
Support Year
5
Fiscal Year
2003
Total Cost
$66,930
Indirect Cost
Name
Texas A&M University
Department
Pathology
Type
Schools of Medicine
DUNS #
141582986
City
College Station
State
TX
Country
United States
Zip Code
77845
Samuel, Shaija; Twizere, Jean-Claude; Beifuss, Katherine K et al. (2008) Nucleolin binds specifically to an AP-1 DNA sequence and represses AP1-dependent transactivation of the matrix metalloproteinase-13 gene. Mol Carcinog 47:34-46
Samuel, Shaija; Beifuss, Katherine K; Bernstein, Lori R (2007) YB-1 binds to the MMP-13 promoter sequence and represses MMP-13 transactivation via the AP-1 site. Biochim Biophys Acta 1769:525-31
Twizere, Jean-Claude; Kruys, Veronique; Lefebvre, Laurent et al. (2003) Interaction of retroviral Tax oncoproteins with tristetraprolin and regulation of tumor necrosis factor-alpha expression. J Natl Cancer Inst 95:1846-59
Kumar, N V; Bernstein, L R (2001) Ten ERK-related proteins in three distinct classes associate with AP-1 proteins and/or AP-1 DNA. J Biol Chem 276:32362-72
Kumar, N V; Bernstein, L R (2001) A new analytical scale DNA affinity binding assay for analyses of specific protein-DNA interactions. Anal Biochem 299:203-10
Kumar, N V; Bernstein, L R (2000) Screening of a cDNA protein expression library by enhanced chemiluminescence detection. Biotechniques 29:418-20, 422, 424
Bernstein, L R; Walker, S E (1999) Tumor promotion resistant cells are deficient in AP-1 DNA binding, JunD DNA binding and JunD expression and form different AP-1-DNA complexes than promotion sensitive cells. Biochim Biophys Acta 1489:263-80